Yarbrough Capital LLC Has $421,000 Stake in Seagen Inc. (NASDAQ:SGEN)

Yarbrough Capital LLC increased its holdings in Seagen Inc. (NASDAQ:SGENGet Rating) by 20.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,920 shares of the biotechnology company’s stock after buying an additional 503 shares during the period. Yarbrough Capital LLC’s holdings in Seagen were worth $421,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SGEN. EverSource Wealth Advisors LLC acquired a new position in Seagen during the fourth quarter valued at approximately $32,000. Leverty Financial Group LLC bought a new stake in shares of Seagen during the fourth quarter worth $35,000. Covestor Ltd bought a new stake in shares of Seagen during the fourth quarter worth $50,000. Reilly Financial Advisors LLC bought a new stake in shares of Seagen during the fourth quarter worth $54,000. Finally, Desjardins Global Asset Management Inc. bought a new stake in shares of Seagen during the fourth quarter worth $69,000. Institutional investors own 90.37% of the company’s stock.

In other Seagen news, EVP Charles R. Romp sold 319 shares of the company’s stock in a transaction dated Wednesday, April 20th. The shares were sold at an average price of $144.32, for a total value of $46,038.08. Following the completion of the sale, the executive vice president now directly owns 49,816 shares of the company’s stock, valued at approximately $7,189,445.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Vaughn B. Himes sold 1,134 shares of the company’s stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $160.00, for a total transaction of $181,440.00. Following the completion of the sale, the insider now directly owns 119,471 shares of the company’s stock, valued at $19,115,360. The disclosure for this sale can be found here. Insiders sold a total of 53,591 shares of company stock valued at $7,516,752 over the last ninety days. 27.30% of the stock is currently owned by insiders.

A number of analysts have weighed in on SGEN shares. StockNews.com started coverage on shares of Seagen in a research note on Thursday, March 31st. They set a “hold” rating on the stock. SVB Leerink boosted their price objective on shares of Seagen from $155.00 to $159.00 and gave the stock an “outperform” rating in a research note on Monday, June 6th. Morgan Stanley boosted their price objective on shares of Seagen from $170.00 to $173.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Oppenheimer boosted their price objective on shares of Seagen from $160.00 to $208.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, JMP Securities reissued a “buy” rating and issued a $157.00 price objective on shares of Seagen in a research note on Wednesday, June 8th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Seagen currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.55.

Shares of SGEN traded up $1.21 on Thursday, reaching $170.87. The company’s stock had a trading volume of 8,823 shares, compared to its average volume of 1,532,640. Seagen Inc. has a twelve month low of $105.43 and a twelve month high of $192.79. The stock has a market capitalization of $31.45 billion, a PE ratio of -45.00 and a beta of 0.85. The firm has a fifty day moving average of $139.65 and a 200-day moving average of $139.95.

Seagen (NASDAQ:SGENGet Rating) last posted its earnings results on Thursday, April 28th. The biotechnology company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.24. Seagen had a negative net margin of 41.32% and a negative return on equity of 21.86%. The company had revenue of $426.50 million for the quarter, compared to analyst estimates of $401.75 million. During the same quarter in the prior year, the business posted ($0.67) EPS. The firm’s revenue was up 28.5% compared to the same quarter last year. Equities research analysts forecast that Seagen Inc. will post -3.5 EPS for the current fiscal year.

About Seagen (Get Rating)

Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

See Also

Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seagen Inc. (NASDAQ:SGENGet Rating).

Institutional Ownership by Quarter for Seagen (NASDAQ:SGEN)

Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.